EcoDrugPlus


Synonyms	API-GP3 FP-GP1 GD-TEXAPHYRIN Gd texaphyrin Gd-Tex Motexafin gadolinium Motexafin gadolinium anhydrous Motexafin gadolinium hydrate NSC-695238 PCI-0120 Xcytrin gadolinium texaphyrin
Status
Molecule Category	UNKNOWN
UNII	6433A42F4F

Synonyms

API-GP3

FP-GP1

GD-TEXAPHYRIN

Gd texaphyrin

Gd-Tex

Motexafin gadolinium

Motexafin gadolinium anhydrous

Motexafin gadolinium hydrate

NSC-695238

PCI-0120

Xcytrin

gadolinium texaphyrin

Status

Molecule Category

UNKNOWN

UNII

6433A42F4F


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Property Name	Value
Molecular Formula	C52H72GdN5O14
Molecular Weight	1148.42
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Property Name

Value

Molecular Formula

C52H72GdN5O14

Molecular Weight

1148.42

AlogP

None

Hydrogen Bond Acceptor

None

Hydrogen Bond Donor

None

Number of Rotational Bond

None

Polar Surface Area

None

Molecular species

None

Aromatic Rings

None

Heavy Atoms

None

Mechanism of Action	Action	Reference
Ribonucleoside-diphosphate reductase RR1 inhibitor	INHIBITOR	PubMed PubMed PubMed PubMed

Mechanism of Action

Action

Reference

Ribonucleoside-diphosphate reductase RR1 inhibitor

INHIBITOR

PubMed PubMed PubMed PubMed

Resources	Reference
ChEMBL	CHEMBL3544910
FDA SRS	6433A42F4F

Resources

Reference

ChEMBL

CHEMBL3544910

FDA SRS

6433A42F4F


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

MOTEXAFIN GADOLINIUM

Physicochemical Descriptors

Bioactivity

Cross References